Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.
Psychedelics
Cybin Acquires DMT Clinical Study from Entheon Biomedical
Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights
Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health
Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.
Optimi Health announces entering into a supply agreement with Halucenex Life Sciences Inc that "pertains to the entirety of" Optimi's recently cultivated psilocybe mushrooms.
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application for the Treatment of Behavioral Addictions
Awakn Life Sciences announces filing a patent application for the treatment of behavioral addictions with ketamine-assisted psychotherapy.
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.
Open For Business: Optimi Completes First Grow of Psilocybin Mushrooms and Introduces Head of Cultivation
Optimi Health announces the completion of its first crop of psilocybin mushrooms at the company's Princeton, B.C. cultivation facility.
Small Pharma Shares Business Update Ahead of Annual Financial Results
Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.
Why Is The Psychedelic Drug Industry Suddenly In Favor With Global Power Players?
The psychedelic drug industry has suddenly attracted the attention of the most influential "power players" on the planet. It's great news for the industry, but...
MindMed Appoints Schond L. Greenway as Chief Financial Officer
MindMed announces the appointment of Schond L. Greenway as its new CFO, bringing a wealth of experience in banking and corporate finance.
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
GH Research reports its Q1 2022 results. Net loss of $5.8 million. Cash position of $270.8 million as of March 31, 2022.
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
Awakn Life Sciences announce promising results from the first study of ketamine-assisted therapy for behavioral addictions, and will be initiating a larger follow-up study.